Evidence map›Paper›PMID 26143067›Full record

Trial reportJournal of gastrointestinal cancer2015

Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.

Joseph Sgouros, Gerasimos Aravantinos, George Kouvatseas, Anna Rapti, George Stamoulis, Anastasios Bisvikis, Helen Res, Epameinondas Samantas

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of gastrointestinal cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph Sgouros3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece. josephsgouros@yahoo.co.uk.
Gerasimos Aravantinos2nd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
George KouvatseasHealth Data Specialists, Ltd, 22 Katehaki Str, Athens, 11525, Greece.
Anna Rapti3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
George Stamoulis3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
Anastasios Bisvikis3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
Helen Res3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
Epameinondas Samantas3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMost stage II or III colorectal cancer patients are receiving nowadays a 4 to 6-month course of adjuvant chemotherapy. However, delays between cycles, reductions in the doses of chemotherapy drugs, or even permanent omissions of chemotherapy cycles might take place due to side effects or patient's preference. We examined the impact of these treatment modifications on recurrence-free survival (RFS) and overall survival (OS).

methodsWe retrospectively collected data from colorectal cancer patients who had received adjuvant chemotherapy in our Department. Patients were categorized in five groups based on whether they had or not delays between chemotherapy cycles, dose reductions, and permanent omissions of chemotherapy cycles. Three-year RFS and OS of the five different groups were compared using the log-rank test and the Sidak approach.

resultsFive hundred and eight patients received treatment. Twenty seven percent of the patients had the full course of chemotherapy; the others had delays, dose reductions, or early termination of the treatment. No statistically significant differences were observed in 3-year RFS and OS between the five groups. A trend for worse RFS was noticed with early termination of treatment. A similar trend was also noticed for OS but only for stage II patients.

conclusionIn colorectal cancer patients, receiving adjuvant chemotherapy, delays between chemotherapy cycles, dose reductions of chemotherapy drugs, or even early termination of the treatment course do not seem to have a negative impact in 3-year RFS and OS; however, due to the trend of worse RFS in patients receiving shorter courses of chemotherapy, further studies are needed.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesAdjuvant chemotherapyColorectal cancerDelays between chemotherapy cyclesDose reductionsOmission of chemotherapy cycles

Identifiers

PMID26143067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.